• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $117,381 worth of shares (3,668 units at $32.00), decreasing direct ownership by 3% to 139,561 units (SEC Form 4)

    6/17/25 4:30:18 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Qatanani Mo

    (Last) (First) (Middle)
    301 BINNEY STREET

    (Street)
    CAMBRIDGE MA 02142

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Scholar Rock Holding Corp [ SRRK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF SCIENTIFIC OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    06/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/16/2025 S 3,668(1) D $32.0014 139,561(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on June 15, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. The shares vested pursuant to awards that were granted on June 16, 2022. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards are fully vested.
    2. Consists of 24,066 shares of common stock and 115,495 RSUs.
    /s/ Junlin Ho, Attorney-in-Fact for Mo Qatanani 06/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SRRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    10/7/2024$30.00 → $35.00Buy
    H.C. Wainwright
    3/28/2024$30.00Strong Buy
    Raymond James
    10/25/2023$20.00Hold → Buy
    Jefferies
    4/3/2023$26.00Overweight
    Piper Sandler
    9/19/2022$30.00Buy
    H.C. Wainwright
    7/12/2022$20.00Buy
    Truist
    3/23/2022$24.00Buy
    H.C. Wainwright
    More analyst ratings

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00 from $40.00 previously

      11/26/24 8:04:27 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $35.00 from $30.00 previously

      10/7/24 9:45:10 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Scholar Rock with a new price target

      Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00

      3/28/24 7:48:04 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    SEC Filings

    See more
    • Scholar Rock Holding Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Scholar Rock Holding Corp (0001727196) (Filer)

      6/18/25 7:10:13 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Scholar Rock Holding Corporation

      144 - Scholar Rock Holding Corp (0001727196) (Subject)

      6/5/25 4:57:15 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Holding Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - Scholar Rock Holding Corp (0001727196) (Filer)

      6/3/25 4:02:04 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $117,381 worth of shares (3,668 units at $32.00), decreasing direct ownership by 3% to 139,561 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      6/17/25 4:30:18 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Peng Katie sold $96,888 worth of shares (3,031 units at $31.97), decreasing direct ownership by 8% to 34,920 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      6/17/25 4:30:19 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • GENERAL COUNSEL Ho Junlin sold $238,154 worth of shares (7,442 units at $32.00), decreasing direct ownership by 3% to 222,569 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      6/17/25 4:30:10 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

      Oral presentation on the positive Phase 3 SAPPHIRE trial of apitegromab for people living with spinal muscular atrophy (SMA), which demonstrated statistically significant improvement and clinically meaningful benefit as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) Apitegromab Biologics License Application (BLA) accepted under priority review for patients with SMA, and U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date set for September 22 European Medicines Agency (EMA) validated Marketing Authorisation Application (MAA) for apitegromab for patients with SMA Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company f

      6/23/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

      Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001) Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide alone lost 13.4% of body weight Higher quality of weight loss observed for patients receiving apitegromab with tirzepatide (85% fat mass/15% lean mass) compared to tirzepatide alone (70% fat mass/30% lean mass) Apitegromab was generally well tolerated, and t

      6/18/25 7:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 309,700 shares of its common stock to 11 newly hired employees, consisting of inducement stock options to purchase an aggregate of 176,963 shares of common stock and inducement restricted stock units, covering an aggregate of 132,737 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 20

      6/13/25 4:15:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:46:02 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:44:33 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/16/23 5:46:56 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

      - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

      8/16/21 4:05:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 9:00:58 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 7:24:55 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 1:22:38 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Financials

    Live finance-specific insights

    See more
    • Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

      Oral presentation on the positive Phase 3 SAPPHIRE trial of apitegromab for people living with spinal muscular atrophy (SMA), which demonstrated statistically significant improvement and clinically meaningful benefit as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) Apitegromab Biologics License Application (BLA) accepted under priority review for patients with SMA, and U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date set for September 22 European Medicines Agency (EMA) validated Marketing Authorisation Application (MAA) for apitegromab for patients with SMA Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company f

      6/23/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

      Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001) Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide alone lost 13.4% of body weight Higher quality of weight loss observed for patients receiving apitegromab with tirzepatide (85% fat mass/15% lean mass) compared to tirzepatide alone (70% fat mass/30% lean mass) Apitegromab was generally well tolerated, and t

      6/18/25 7:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 309,700 shares of its common stock to 11 newly hired employees, consisting of inducement stock options to purchase an aggregate of 176,963 shares of common stock and inducement restricted stock units, covering an aggregate of 132,737 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 20

      6/13/25 4:15:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care